There are currently 13 active clinical trials seeking participants for Venous Thromboembolism research studies. The states with the highest number of trials for Venous Thromboembolism participants are .
PRospective Evaluation of Peripartum Anticoagulation ManaGement for ThrOmboembolism
NCT05756244
Recruiting
The PREP and GO study is an international multicentre prospective cohort evaluating anticoagulation management strategies around labor and delivery and the postpartum period.
Gender:
FEMALE
Ages:
Between 18 years and 60 years
Trial Updated:
07/29/2025
Locations: Duke University Hospital, Durham, North Carolina +9 locations
Conditions: Pregnancy Related, Venous Thromboembolism
Register for Updates
Reducing Gastrointestinal Bleeding With Proton Pump Inhibitor Therapy in Acute Venous Thromboembolism
NCT06393868
Recruiting
The investigators are studying whether treatment with a proton pump inhibitor called omeprazole reduces gastrointestinal bleeding in older adults taking blood thinners for a blood clot (venous thromboembolism). The purpose of this study, a pilot study or a feasibility study, is to test the study plan and determine whether enough participants will join a larger study and accept the study procedures.
Gender:
ALL
Ages:
65 years and above
Trial Updated:
07/28/2025
Locations: The Ottawa Hospital, Ottawa, Ontario +2 locations
Conditions: Venous Thromboembolism, Gastro Intestinal Bleeding, Blood Clot
Register for Updates
A Trial to Learn How Well REGN9933 and REGN7508 Work for Preventing Blood Clots, and How Safe They Are, in Adults Who Have a Peripherally Inserted Central Catheter (PICC)
NCT06299111
Recruiting
This study is researching 2 different experimental drugs called REGN9933 and REGN7508 (called "study drugs"). The study is focused on adults undergoing a placement of a catheter in the vein, also called a 'PICC line'. The aim of the study is to see how effective the study drug is at preventing venous thromboembolism (VTE) and other related disease after catheter placement. The study is looking at several other research questions, including: * What side effects may happen from taking the study... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/09/2025
Locations: Brigham and Women's Hospital, Boston, Massachusetts +17 locations
Conditions: Venous Thromboembolism
Register for Updates
Colchicine to Quench the Inflammatory Response After Deep Vein Thrombosis (The Conquer-DVT Pilot Trial)
NCT06440694
Recruiting
This trial seeks to assess the feasibility of a full-scale, double-blind, placebo-controlled, randomized trial assessing whether low-dose colchicine (0.5 mg daily) reduces the risk of post-thrombotic syndrome (PTS) in patients with proximal lower extremity deep vein thrombosis (DVT).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/09/2025
Locations: The Ottawa Hospital General Campus, Ottawa, Ontario
Conditions: Venous Thromboembolism
Register for Updates
VTE Prevention With Rivaroxaban in Genitourinary Cancer Patients Receiving Systemic Therapy
NCT05920343
Recruiting
Patients with genitourinary cancers (ex: bladder, testicular, kidney) are at high risk of developing blood clots if they receive systemic therapy (ex: chemotherapy, immunotherapy). Blood clots cause pain, may require hospitalization and invasive testing, and in some cases cause death. In fact, blood clots are one of the leading causes of death in patients with cancer. Furthermore, patients who develop a blood clot require medication to thin the blood for a prolonged (sometimes indefinite) period... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/08/2025
Locations: Ottawa Hospital Research Institute, Ottawa, Ontario
Conditions: Venous Thromboembolism, Urologic Cancer
Register for Updates
Primary Thromboprophylaxis in Patients With Malignancy and Central Venous Catheters
NCT05029063
Recruiting
The purpose of the full trial is to determine the efficacy and safety of prophylactic dose rivaroxaban to prevent VTE among cancer patients with CVC.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/03/2025
Locations: Nova Scotia Health, Halifax, Nova Scotia +10 locations
Conditions: Venous Thromboembolism, Cancer
Register for Updates
Statins for Venous Event Reduction in Patients With Venous Thromboembolism
NCT04319627
Recruiting
The standard or usual treatment for patients diagnosed with deep vein thrombosis or pulmonary embolism is treatment with blood thinners (called anticoagulants). While treatment of blood clots with blood thinners is effective, some research has shown that adding a statin (medication used to lower cholesterol) may give extra protection. It is thought that statins can improve how cells along the walls of the vein control inflammation, which can prevent new blood clots from forming. The medication... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/23/2025
Locations: Foothills Medical Centre, Calgary, Alberta +17 locations
Conditions: Venous Thromboembolism, Blood Clot, Post Thrombotic Syndrome
Register for Updates
Secondary Prevention of VTE in Patients With Cancer and Catheter-Related Upper Extremity Deep Vein Thrombosis
NCT06603870
Recruiting
This trial seeks to evaluate a management strategy after the acute treatment duration (≥ 3 months of therapeutic anticoagulation) for patients with cancer and catheter-related upper extremity deep vein thrombosis (DVT).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/26/2025
Locations: The Ottawa Hospital, Ottawa, Ontario
Conditions: Venous Thromboembolism, Cancer, Upper Extremity Deep Vein Thrombosis, Catheter-Related Infections
Register for Updates
Clinical Surveillance vs. Anticoagulation for Low-risk Patients With Isolated Subsegmental Pulmonary Embolism
NCT04263038
Recruiting
The clinical significance of pulmonary embolism (PE) limited to the subsegmental pulmonary arteries, so called isolated subsegmental pulmonary embolism (SSPE), remains controversial. Whether isolated SSPE represents "true" PE, a clinically more benign form of PE, a physiologic lung clearing process, or a false positive result (artifact) is currently unclear and hence, whether patients with isolated SSPE benefit from anticoagulant treatment is uncertain. Despite growing evidence from observationa... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/23/2025
Locations: Centre hospitalier universitaire de Liege, Liège, Not set +38 locations
Conditions: Pulmonary Embolism, Embolism, Embolism and Thrombosis, Lung Diseases, Cardiovascular Diseases, Respiratory Tract Diseases, Venous Thromboembolism, Anticoagulant-induced Bleeding, Bleeding
Register for Updates
A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE
NCT05171075
Recruiting
This is a Phase 3, multicenter, open-label, blinded endpoint study to evaluate the effect of abelacimab relative to dalteparin on venous thromboembolism (VTE) recurrence and bleeding in patients with gastrointestinal (GI)/genitourinary (GU) cancer associated VTE (Magnolia)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/18/2024
Locations: University of Colorado Anschutz Medical Campus, Aurora, Colorado +184 locations
Conditions: Venous Thromboembolism, Deep Venous Thrombosis, Pulmonary Embolism
Register for Updates
A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTE
NCT05171049
Recruiting
This is a Phase 3,multicenter, randomized, open-label, blinded endpoint evaluation study comparing the effect of abelacimab relative to apixaban on venous thromboembolism (VTE) recurrence and bleeding in patients with cancer associated VTE (ASTER)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/18/2024
Locations: University of Colorado Anschutz Medical Campus, Aurora, Colorado +218 locations
Conditions: Venous Thromboembolism, Deep Venous Thrombosis, Pulmonary Embolism
Register for Updates
VTE Prevention Following Total Hip and Knee Arthroplasty
NCT04075240
Recruiting
Consented patients undergoing elective total hip and total knee arthroplasty will be randomized to receive either aspirin alone or aspirin and rivaroxaban for prevention of venous thromboembolism.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/06/2024
Locations: Queen Elizabeth II HSC, Halifax, Nova Scotia
Conditions: Venous Thromboembolism
Register for Updates